PCRX
Pacira BioSciences, Inc.
NASDAQ: PCRX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$25.12
-1.72% today
Updated 2026-09-25
Market cap
$971.89M
P/E ratio
68.61
P/S ratio
1.30x
EPS (TTM)
$0.36
Dividend yield
—
52W range
$19 – $28
Volume
0.6M
WallStSmart proprietary scores
42
out of 100
Grade: D
Sell
Investment rating
4.0
Growth
C7.5
Quality
B+4.5
Profitability
C4.7
Valuation
C7/9
Piotroski F-Score
Strong
1.6
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →261 stocks currently score above 75
Price targets
Analyst target
$29.75
+18.43%
12-Month target
$1.09
-95.66%
Intrinsic (DCF)
$179.51
Margin of safety
+87.89%
1 Strong Buy3 Buy2 Hold0 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
+ Piotroski 7/9 — strong financial health
+ Free cash flow $56.12M — positive
+ 87.89% below intrinsic value
Risks
- Altman Z 1.57 — distress zone
- Thin margins at 1.96%
- P/E 68.61x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $666.82M | $674.98M | $700.97M | $726.41M | $746.16M |
| Net income | $15.91M | $41.95M | $-99.56M | $7.03M | $4.65M |
| EPS | — | — | — | — | $0.36 |
| Free cash flow | $115.20M | $139.49M | $178.75M | $136.66M | $56.12M |
| Profit margin | 2.39% | 6.22% | -14.20% | 0.97% | 1.96% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-08-17 | SLONIN, JONATHAN | Sale | 3,040 | $23.23 |
| 2026-06-11 | RIKER, LAUREN | Sale | 6,115 | $23.50 |
| 2026-06-10 | YOUNG, ALETHIA | Buy | 10,891 | — |
Peer comparison
Smart narrative
Pacira BioSciences, Inc. trades at $25.12. representing a P/E of 68.61x trailing earnings. Our Smart Value Score of 42/100 indicates the stock is fair. The company scores 7/9 on the Piotroski F-Score. With an Altman Z-Score of 1.57, it sits in the distress. TTM revenue stands at $746.16M. with profit margins at 1.96%. Our DCF model estimates intrinsic value at $179.51.
Frequently asked questions
What is Pacira BioSciences, Inc.'s stock price?
Pacira BioSciences, Inc. (PCRX) trades at $25.12, on a P/E of 68.6x and a P/S of 1.3x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Pacira BioSciences, Inc. overvalued?
Pacira BioSciences, Inc. carries a Smart Value Score of 42/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $179.51 versus the $25.12 price, a 87.9% margin of safety on a cash flow basis.
What is the price target of Pacira BioSciences, Inc. (PCRX)?
The 12-month analyst consensus target is $29.75, about 18.4% above the current $25.12. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Pacira BioSciences, Inc. (PCRX)?
Our DCF model estimates intrinsic value at $179.51, a +87.9% margin of safety versus today's $25.12. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Pacira BioSciences, Inc.'s revenue?
Pacira BioSciences, Inc.'s trailing twelve-month revenue is $746.16M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Pacira BioSciences, Inc.'s Altman Z-Score is 1.57, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.30x
ROE2.18%
Beta0.27
50D MA$25.31
200D MA$23.89
Shares out0.04B
Float0.04B
Short ratio—
Avg volume0.6M
Performance
1 week+1.74%
1 month-2.48%
3 months-0.48%
YTD-2.94%
1 year-0.48%
3 years—
5 years—